Proatherogenic high-density lipoprotein, vascular inflammation, and mimetic peptides

Current Atherosclerosis Reports

Volumn 10, Issue 2, 2008, Pages 171-176

  Yu, Roger ^b   Yekta, Babak ^b   Vakili, Ladan ^b   Gharavi, Navid ^b   Navab, Mohamad ^a   Marelli, Daniel ^b   Ardehali, Abbas ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN A1; CARDIOVASCULAR AGENT; ENDOTOXIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; PEPTIDE; PEPTIDE 4F; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC GRAFT REJECTION; DIABETES MELLITUS; DISEASE SEVERITY; DRUG POTENCY; DYSLIPIDEMIA; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; INFECTION; INFLAMMATION; INFLUENZA VIRUS A; KIDNEY DISEASE; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; OXIDATIVE STRESS; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SCLERODERMA; SICKLE CELL ANEMIA; STREPTOZOCIN DIABETES; VIRUS PNEUMONIA;

ANIMALS; APOLIPOPROTEIN A-I; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; INFLAMMATION; INTERLEUKINS; KIDNEY DISEASES; LIPOPROTEINS, HDL; OXIDATION-REDUCTION; OXIDATIVE STRESS; PEPTIDES;

EID: 41749100855     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-008-0025-z     Document Type: Review

References (36)

1. Badimon JJ, Badimon L, Fuster V: Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990, 85:1234-1241.
2. Plump AS, Scott CJ, Breslow JL: Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A 1994, 91:9607-9611.
3. Nissen SE, Tsunoda T, Tuzcu EM, et al.: Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292-2300.
4. Tardif JC, Gregoire J, L'Allier PL, et al.: Effect of rHDL on atherosclerosis-safety and efficacy [ERASE] investigators. JAMA 2007, 297:1675-1682.
5. Anantharamaiah GM, Jones JL, Brouillette CG, et al.: Studies of synthetic peptide analogs of amphipathic helix I: structure of peptide/ DMPC complexes. J Biol Chem 1985, 260:10248-10255.
6. Venkatachalapathi YV, Phillips MC, Epand RM, et al.: Effect of end group blockage on the properties of a class A amphipathic helical peptide. Proteins Structure Function Genet 1993, 15:349-359.
7. Yancey PG, Bielicki JK, Lund-Katz S, et al.: Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides. Biochemistry 1995, 34:7955-7965.
8. Datta G, Chaddha M, Hama S, et al.: Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res 2001, 42:1096-1104.
9. Fogelman AM: When pouring water on the fire makes it burn brighter. Cell Metab 2005, 2:6-8.
10. Wu BJ, Kathir K, Witting PK, et al.: Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. Exp Med 2006, 203:1117-1127.
11. Stocker R, Perrella MA: Heme oxygenase-1: a novel drug target for atherosclerotic diseases? Circulation 2006, 114:2178-2189.
12. Gharavi NM, Gargalovic PS, Chang I, et al.: High-density lipoprotein modulates oxidized phospholipid signaling in human endothelial cells from proinflammatory to anti-inflammatory. Arterioscler Thromb Vasc Biol 2007, 27:1346-1353.
13. Navab M, Anantharamaiah GM, Hama S, et al.: Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002, 105:290-292.
14. Navab M, Anantharamaiah GM, Reddy ST, et al.: Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 2004, 109:3215-3220.
15. Li X, Chyu KY, Faria JR, et al.: Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 2004, 110:1701-1705.
16. Navab M, Anantharamaiah GM, Hama S, et al.: D-4F and statins synergize to render HDL anti-inflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Tbromb Vasc Biol 2005, 25:1426-1432.
17. Navab M, Anantharamaiah GM, Reddy ST, et al.: An oral apoJ peptide renders HDL anti-inflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005, 25:1932-1937.
18. Navab M, Anantharamaiah GM, Reddy ST, et al.: Oral small peptides render HDL anti-inflammatory in mice and monkeys and reduce atherosclerosis in apoE null mice. Circ Res 2005, 97:524-532.
19. Van Lenten BJ, Wagner A, Navab M, Fogelman AM: Circulation 2007 [Epub ahead of print].
20. Navab M, Anantharamaiah GM, Reddy ST, et al.: Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 2005, 25:1325-1331.
21. Berliner JA, Watson AD: A role for oxidized phospholipids in atherosclerosis. N Engl J Med 2005, 353:9-12.
22. Gargalovic PS, Imura M, Zhang B, et al.: Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids. Proc Natl Acad Sci U S A 2006, 103:12741-12746.
23. Van Lenten BJ, Wagner AC, Anantharamaiah GM, et al.: Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation 2002, 106:1127-1132.
24. Van Lenten BJ, Wagner AC, Navab M, et al.: D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation 2004, 110:3252-3258.
25. Gupta H, Dai L, Datta G, et al.: Inhibition of lipo-polysaccharide-induced inflammatory responses by an apolipoprotein Al mimetic peptide. Circ Res 2005, 97:236-243.
26. Buga GM, Frank JS, Mottino GA, et al.: D-4F decreases brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a Western diet. J Lipid Res 2006, 47:2148-2160.
27. Kruger AL, Peterson S, Turkseven S, et al.: D-4F induces heme oxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloghing, and improves vascular reactivity in rat model of diabetes. Circulation 2005, 111:3126-3134.
28. Peterson SJ, Husney D, Kruger AL, et al.: Long-term treatment with the apolipoprotein A1 mimetic peptide increases antioxidants and vascular repair in type I diabetic rats. J Pharmacol Exp Ther 2007, 322:514-520.
29. Araujo JA, Meng L, Tward AD, et al.: Systemic rather than local heme oxygenase-1 overexpression improves cardiac allograft outcomes in a new transgenic mouse. J Immunol 2003, 171:1572-1580.
30. Schnickel GT, Hsieh GR, Kachikwu EL, et al.: Cytoprotective gene HO-1 and chronic rejection in heart transplantation. Transplant Proc 2006, 38:3259-3262.
31. Hsieh GR, Schnickel GT, Garcia C, et al.: Inflammation/oxidation in chronic rejection: apolipoprotein A-I mimetic peptide reduces chronic rejection of transplanted hearts. Transplantation 2007, 84:238-243.
32. Ou Z, Ou J, Ackerman AW, et al.: L-4F, an apolipoprotein A-1 mimetic, restores nitric oxide and superoxide anion balance in low-density lipoprotein-treated endothelial cells. Circulation 2003, 107:1520-1524.
33. Ou J, Ou Z, Jones DW, et al.: L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 2003, 107:2337-2341.
34. Ou J, Wang J, Xu H, et al.: Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double knockout mice on Western diet. Circ Res 2005, 97:1190-1197.
35. Weihrauch D, Xu H, Shi Y, et al.: Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice. Am J Physiol Heart Circ Physiol 2007, 293:H1432-H1441.
36. Buga GM, Frank JS, Mottino GA, et al.: D-4F Reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor null mice fed a Western diet. J Lipid Res 2007, [Epub ahead of print].